CONCLUSIONS: The core components of our approach-biopsychosocial assessment and multimodal treatment planning with an emphasis on promoting functional goals and safety using clear communication and a patient-centered stance-should guide providers in the management of similar clinical scenarios. More evidence is needed to definitively guide specific interventions and points of clinical equipoise.
PMID: 26818474 [PubMed – in process] (Source: Addiction Science and Clinical Practice)

CONCLUSIONS: The core components of our approach-biopsychosocial assessment and multimodal treatment planning with an emphasis on promoting functional goals and safety using clear communication and a patient-centered stance-should guide providers in the management of similar clinical scenarios. More evidence is needed to definitively guide specific interventions and points of clinical equipoise.
PMID: 26818474 [PubMed – in process] (Source: Addiction Science and Clinical Practice)

A group of researchers at Boston Medical Center recently looked at nearly 3,000 patients who had survived an opioid-related overdose between 2000 and 2012. According to their recently published study, over 90% of these patients continued to receive opioid medications from doctors — even after their overdose. Given the soaring numbers of opioid-related overdose deaths and heightened scrutiny on how these medications are being over-prescribed, the study findings are alarming and disturbing.
The researchers identified almost 3,000 patients nationwide who had had a nonfatal overdose while being treated with opioid medications for chronic pain. These patients were followed for 300 days, on average, after their overdose. During those 300 days, an additional 7% of the patients overdosed a secon…

A group of researchers at Boston Medical Center recently looked at nearly 3,000 patients who had survived an opioid-related overdose between 2000 and 2012. According to their recently published study, over 90% of these patients continued to receive opioid medications from doctors — even after their overdose. Given the soaring numbers of opioid-related overdose deaths and heightened scrutiny on how these medications are being over-prescribed, the study findings are alarming and disturbing.
The researchers identified almost 3,000 patients nationwide who had had a nonfatal overdose while being treated with opioid medications for chronic pain. These patients were followed for 300 days, on average, after their overdose. During those 300 days, an additional 7% of the patients overdosed a secon…

Preoperative narcotic use has been associated with poor outcomes after total joint arthroplasty (TJA). The purpose of this study is to compare clinical outcomes of patients undergoing elective TJA while concurrently being treated with methadone or buprenorphine/naloxone for prior heroin addiction to a matched control group. (Source: The Journal of Arthroplasty)

Preoperative narcotic use has been associated with poor outcomes following total joint arthroplasty (TJA). The purpose of this study is to compare clinical outcomes of patients undergoing elective TJA while concurrently being treated with methadone or buprenorphine/naloxone for prior heroin addiction to a matched control group. (Source: The Journal of Arthroplasty)

Preoperative narcotic use has been associated with poor outcomes following total joint arthroplasty (TJA). The purpose of this study is to compare clinical outcomes of patients undergoing elective TJA while concurrently being treated with methadone or buprenorphine/naloxone for prior heroin addiction to a matched control group. (Source: The Journal of Arthroplasty)

Any high school in the U.S. that wants to carry an emergency opioid overdose reversal kit will now be able to get one free of charge, thanks to a new initiative announced Monday by the Clinton Foundation and the drug’s manufacturer. Adapt Pharma, manufacturers of a nasal-spray form of naloxone, also known as Narcan, has partnered with the Clinton Health Matters Initiative to further expand access to the life-saving drug, the two groups said at the final day of the Clinton Health Matters Initiative Activation Summit. Naloxone is nonaddictive, nontoxic and easy to administer, especially through nasal application. It reverses the effects of an opioid overdose by essentially blocking the opioid receptors that heroin and many prescription painkillers target. The U.S. Food and Drug Administ…

Any high school in the U.S. that wants to carry an emergency opioid overdose reversal kit will now be able to get one free of charge, thanks to a new initiative announced Monday by the Clinton Foundation and the drug’s manufacturer. Adapt Pharma, manufacturers of a nasal-spray form of naloxone, also known as Narcan, has partnered with the Clinton Health Matters Initiative to further expand access to the life-saving drug, the two groups said at the final day of the Clinton Health Matters Initiative Activation Summit. Naloxone is nonaddictive, nontoxic and easy to administer, especially through nasal application. It reverses the effects of an opioid overdose by essentially blocking the opioid receptors that heroin and many prescription painkillers target. The U.S. Food and Drug Administ…

LAKE FOREST, Ill., Jan. 19, 2016 — (Healthcare Sales & Marketing Network) — Akorn, Inc. (AKRX), a leading specialty generic pharmaceutical company, today announced that it has launched Buprenorphine and Naloxone Sublingual Tablets CIII in 2mg/0.5mg and 8… Biopharmaceuticals, Generics, Product LaunchAkorn, Buprenorphine, Naloxone, Tobramycin (Source: HSMN NewsFeed)